Farrukh Awan is an Oncology physician affiliated with Southwestern Medical Center. OpenAlex indexes 451 publications with 9,279 citations (h-index 48); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6201 Harry Hines Blvd Mail Code 8565
Dallas, TX 75390
Telephone
214-645-4673Registry record last updated 21 Nov 2018.
Clinical trials
- IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Sponsor: University of Texas Southwestern Medical Center
- Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Sponsor: Xencor, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeiGene USA, Inc.Program year20255 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
30.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.6%Acyclovir100%Part D≥112 patientsCorticosteroid3.1%Methylprednisolone100%Part D≥51 patientsCancer & immunology
22.9%Kinase inhibitor20.3%Calquence79%Imbruvica9%Jaypirca6%Brukinsa6%Part D<11 patientsBCL-2 Inhibitor1.5%Venclexta100%Part D<11 patients+ 1 more class in this area
Anti-infectives
18.9%Short-acting sulfonamides9.9%Sulfamethoxazole-Trimethoprim100%Part D≥48 patientsFluoroquinolone Antibacterial3.7%Levofloxacin100%Part D≥50 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Claus Roehrborn, MD
Southwestern Medical Center
Trish Perl, MD
Southwestern Medical Center
Lisa Vanwagner, MD
Southwestern Medical Center
Jose Joglar, MD
Southwestern Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”